Veru Inc is trading at $3.08 (-5.37%) as the stock faces profit-taking following a sharp rally tied to its clinical supply agreement with Novo Nordisk.
- The stock is retreating after a +10.51% close on June 11, 2026, which was driven by news of the enobosarm obesity trial partnership.
- Investors appear to be locking in gains following the recent surge and amid ongoing market volatility.
- The agreement with Novo Nordisk to supply Wegovy for Veru's Phase 2b trial remains a primary catalyst for the stock's recent price action.